April 2026
Depression
What April 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
In April 2026, research on depression focused heavily on treatment-resistant depression (TRD), with multiple studies examining ketamine/esketamine, psilocybin, and other novel agents. Findings were mixed: meta-analyses of psilocybin showed large effect sizes but low certainty due to methodological issues like waitlist controls and unblinding, while ketamine/esketamine studies reported rapid but often transient antidepressant effects. A key caveat is that most evidence comes from small, open-label, or short-term studies, limiting the durability and generalizability of conclusions.
Confidence in the evidence
Low-Moderate- Multiple meta-analyses (e.g., psilocybin with N=514 and N=606) show large effect sizes but low GRADE certainty due to risk of bias, heterogeneity, and publication bias.
- Several studies are small (e.g., N=14, N=34, N=8) or open-label, increasing risk of bias and limiting generalizability.
- Evidence is consistent in showing rapid antidepressant effects for ketamine/esketamine and psilocybin, but durability and long-term efficacy remain unclear.
- Head-to-head comparisons (e.g., rTMS vs. esketamine) and systematic reviews (e.g., ECT vs. ketamine) highlight heterogeneity in dosing and follow-up, complicating definitive conclusions.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Pharmacological augmentation in treatment-resistant depression: a neurobiologically informed, practical decision guide for treatment choice with lithium, quetiapine, or esketamine. 2026 | narrative review | Unclear | Lithium, quetiapine, and esketamine differ in profile but converge on neuroplasticity pathways; validated predictive markers for differential response are lacking. | |
| From synapse to strategy: a bibliometric map of ionotropic glutamate receptors in depression. 2026 | bibliometric analysis | 6843 | Unclear | Research on ionotropic glutamate receptors in depression has grown 7.31% annually, with NMDA receptor and treatment-resistant depression as primary hotspots. |
| Baseline EEG Temporal Dynamics as a Thalamic Filter State Biomarker: A Thalamic Filter Model Account of Ketamine Antidepressant Response Prediction and Depression as Thalamic Over-Filtering 2026 | theoretical | Unclear | The Thalamic Filter Model proposes that depression involves thalamic over-filtering and that baseline EEG dynamics may predict ketamine response. | |
| Repeated intranasal esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series. 2026 | prospective case series | 8 | Supports | Intranasal esketamine reduced depressive symptoms by 48.8% at Week 12, with 50% achieving depression response. |
| Media hype regarding psychedelic treatments for depression and PTSD from 2017 to 2024 2026 | observational | 6805 | Unclear | Media coverage of psychedelics uses more positive emotion and less risk language compared to antidepressants, which may impact patient expectations. |
| Treatment of major depressive disorder and treatment resistant depression with 5-MeO-DMT: Impact of 25 years of non-traditional public scientific communication and education on clinical development and commercialization 2026 | theoretical | Unclear | Informal and underground use of 5-MeO-DMT has contributed knowledge on alleviating depressive symptoms, but legal barriers delay formal clinical investigation. | |
| Characterising the clinical associations of hallucinogen persisting perception disorder: a retrospective cohort study 2026 | retrospective cohort | 25778 | Unclear | Among HPPD patients, 29.2% had depressive episodes prior to diagnosis; anxiety and post-viral fatigue predicted HPPD development in psychedelic users. |
| The Monoamine-Glutamate Continuum of Depression: A Neurobiological Framework for Precision Psychiatry. 2026 | narrative review | Unclear | Evidence suggests depressive syndromes may reflect varying contributions of monoaminergic dysregulation and glutamatergic-neuroplastic impairment. | |
| Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression. 2026 | open-label Phase 2 trial | 14 | Supports | Higher baseline IL-6 levels were associated with more rapid symptom reduction with esketamine, suggesting IL-6 as a candidate biomarker. |
| Ayahuasca Therapy: Possible Reduction of Suicidal Ideation in Treatment-Resistant Depression - A Systematic Review. 2026 | systematic review | 5 | Supports | Ayahuasca administration is consistently associated with rapid and significant reductions in suicidal ideation and depressive symptoms across five studies. |
| Efficacy and Safety of Psilocybin-Assisted Therapy for Depression: A Meta-Analysis of Randomised Controlled Trials 2026 | meta-analysis | 514 | Supports | Psilocybin therapy showed a large pooled effect size (SMD=1.270) for symptom reduction, but GRADE certainty was low due to risk of bias and heterogeneity. |
| The efficacy and safety of psilocybin-assisted therapy for major depressive disorder: a meta-analytic review of clinical outcomes 2026 | meta-analysis | 606 | No effect | The pooled standardized mean difference (-0.79) was not statistically significant, with extreme heterogeneity; effect was highly context-dependent on trial design. |
| Esketamine-sufentanil PCA reduces postoperative depression state in elderly colorectal cancer patients: a randomized controlled trial. 2026 | RCT | 99 | Supports | Low-dose esketamine (1 mg/kg) adjunct to sufentanil PCA significantly reduced postoperative depression and anxiety scores compared to control. |
| Neuroscientific Basis of Ketamine as an Analgesic and Emerging Role in the Management of Depression. 2026 | narrative review | Supports | Ketamine and esketamine have demonstrated rapid antidepressant effects in MDD and TRD, but require careful patient selection and monitoring. | |
| Psilocybin reshapes cortical inhibition through selective interneuron recruitment. 2026 | preclinical | Unclear | Psilocybin reduces firing of somatostatin-expressing interneurons and increases activity of parvalbumin-expressing interneurons in mouse medial frontal cortex. | |
| Innovative Approaches to Depression Therapy: The Antidepressant Efficacy and Mechanisms of General Anesthetics. 2026 | narrative review | Supports | Several general anesthetics, including ketamine, propofol, and isoflurane, exhibit rapid and sustained antidepressant effects in preclinical and clinical settings. | |
| Comparison of average time-to-relapse following ECT versus ketamine - A systematic review. 2026 | systematic review | 13 | Mixed | Both ECT and ketamine show sustained therapeutic potential, with ECT possibly associated with longer remission; increased dose and maintenance prolong remission. |
| Ketamine Use in Critically Ill Patients: Insights into Depressive Symptoms and Hemodynamic Changes. 2026 | retrospective | 34 | Supports | Subanesthetic ketamine infusions were associated with improvement in apparent sadness (90.0% vs 52.2%) and reported sadness (95.0% vs 59.1%) in ICU patients. |
| A systematic review of ketamine and esketamine-induced long-term potentiation and synaptic scaling: Do the molecular and synaptic plasticity effects inform dosing intervals? 2026 | systematic review | 78 | Supports | A single 0.5 mg/kg IV ketamine infusion produced rapid but transient antidepressant effects peaking at 24 hours and declining over 2-3 days. |
| Psilocybin in Older Adults: Therapeutic Opportunities in Inflammation-Driven Disorders of Aging—From Depression to Neurodegeneration 2026 | theoretical | Unclear | Psilocybin is discussed as a therapeutic opportunity in inflammation-driven disorders of aging, including depression and neurodegeneration. | |
| Comparison of rTMS and esketamine for treatment-resistant depression: A target trial emulation. 2026 | observational | 3380 | Mixed | rTMS was associated with a higher risk of suicide-related outcomes compared to esketamine (HR 1.199, not significant), but lower risk of hospitalization (HR 0.746). |
| Filtering the noise: a cerebellar-centered framework for understanding and treating mental illness -a paradigm shift in psychiatry 2026 | theoretical | Unclear | A cerebellar-centered framework is proposed, suggesting psychiatric conditions stem from breakdowns in sensory filtering mechanisms. | |
| Sustained effectiveness and safety of esketamine for major depressive disorder: a target trial simulation of real-world data. 2026 | observational | Unclear | This target trial simulation of real-world data evaluates sustained effectiveness and safety of esketamine for MDD. | |
| Evaluation of a facilitator training program in a randomized controlled trial of psilocybin treatment for depression. 2026 | qualitative | 9 | Unclear | Nurses reported that online and on-site training supported knowledge acquisition, but most felt additional practical training was needed for psilocybin facilitation. |
| [LSD revisited: Mechanisms of action and therapeutic potential in mental health]. 2026 | narrative review | Unclear | LSD's modulation of 5-HT2A and glutamatergic systems is hypothesized to underlie rapid antidepressant responses, but methodological hurdles like placebo control remain. |
Lithium, quetiapine, and esketamine differ in profile but converge on neuroplasticity pathways; validated predictive markers for differential response are lacking.
narrative review
Research on ionotropic glutamate receptors in depression has grown 7.31% annually, with NMDA receptor and treatment-resistant depression as primary hotspots.
bibliometric analysis Sample size: 6843
The Thalamic Filter Model proposes that depression involves thalamic over-filtering and that baseline EEG dynamics may predict ketamine response.
theoretical
Intranasal esketamine reduced depressive symptoms by 48.8% at Week 12, with 50% achieving depression response.
prospective case series Sample size: 8
Media coverage of psychedelics uses more positive emotion and less risk language compared to antidepressants, which may impact patient expectations.
observational Sample size: 6805
Informal and underground use of 5-MeO-DMT has contributed knowledge on alleviating depressive symptoms, but legal barriers delay formal clinical investigation.
theoretical
Among HPPD patients, 29.2% had depressive episodes prior to diagnosis; anxiety and post-viral fatigue predicted HPPD development in psychedelic users.
retrospective cohort Sample size: 25778
Evidence suggests depressive syndromes may reflect varying contributions of monoaminergic dysregulation and glutamatergic-neuroplastic impairment.
narrative review
Higher baseline IL-6 levels were associated with more rapid symptom reduction with esketamine, suggesting IL-6 as a candidate biomarker.
open-label Phase 2 trial Sample size: 14
Ayahuasca administration is consistently associated with rapid and significant reductions in suicidal ideation and depressive symptoms across five studies.
systematic review Sample size: 5
Psilocybin therapy showed a large pooled effect size (SMD=1.270) for symptom reduction, but GRADE certainty was low due to risk of bias and heterogeneity.
meta-analysis Sample size: 514
The pooled standardized mean difference (-0.79) was not statistically significant, with extreme heterogeneity; effect was highly context-dependent on trial design.
meta-analysis Sample size: 606
Low-dose esketamine (1 mg/kg) adjunct to sufentanil PCA significantly reduced postoperative depression and anxiety scores compared to control.
RCT Sample size: 99
Ketamine and esketamine have demonstrated rapid antidepressant effects in MDD and TRD, but require careful patient selection and monitoring.
narrative review
Psilocybin reduces firing of somatostatin-expressing interneurons and increases activity of parvalbumin-expressing interneurons in mouse medial frontal cortex.
preclinical
Several general anesthetics, including ketamine, propofol, and isoflurane, exhibit rapid and sustained antidepressant effects in preclinical and clinical settings.
narrative review
Both ECT and ketamine show sustained therapeutic potential, with ECT possibly associated with longer remission; increased dose and maintenance prolong remission.
systematic review Sample size: 13
Subanesthetic ketamine infusions were associated with improvement in apparent sadness (90.0% vs 52.2%) and reported sadness (95.0% vs 59.1%) in ICU patients.
retrospective Sample size: 34
A single 0.5 mg/kg IV ketamine infusion produced rapid but transient antidepressant effects peaking at 24 hours and declining over 2-3 days.
systematic review Sample size: 78
Psilocybin is discussed as a therapeutic opportunity in inflammation-driven disorders of aging, including depression and neurodegeneration.
theoretical
rTMS was associated with a higher risk of suicide-related outcomes compared to esketamine (HR 1.199, not significant), but lower risk of hospitalization (HR 0.746).
observational Sample size: 3380
A cerebellar-centered framework is proposed, suggesting psychiatric conditions stem from breakdowns in sensory filtering mechanisms.
theoretical
This target trial simulation of real-world data evaluates sustained effectiveness and safety of esketamine for MDD.
observational
Nurses reported that online and on-site training supported knowledge acquisition, but most felt additional practical training was needed for psilocybin facilitation.
qualitative Sample size: 9
LSD's modulation of 5-HT2A and glutamatergic systems is hypothesized to underlie rapid antidepressant responses, but methodological hurdles like placebo control remain.
narrative review
Points of agreement
- Ketamine and esketamine consistently show rapid antidepressant effects in treatment-resistant depression across multiple study designs.
- Psilocybin-assisted therapy shows large effect sizes in meta-analyses, but these are heavily qualified by methodological limitations such as waitlist controls and unblinding.
- Inflammatory markers (e.g., IL-6) and neuroplasticity pathways are increasingly implicated in depression and treatment response.
- Treatment-resistant depression remains a major focus, with a need for biomarker-guided and personalized treatment approaches.
Conflicts
- One meta-analysis of psilocybin (N=514) found a large significant effect, while another (N=606) found a non-significant pooled effect, highlighting sensitivity to inclusion criteria and analytic methods.
- Head-to-head comparisons of rTMS vs. esketamine show mixed results: rTMS had higher suicide risk but lower hospitalization risk, with effects varying by age and sex.
- ECT may be associated with longer remission than ketamine, but evidence is limited by heterogeneity in dosing and follow-up.
Gaps
- Durability of antidepressant effects beyond short-term follow-up is poorly characterized for ketamine, esketamine, and psilocybin.
- Validated biomarkers for predicting differential treatment response are lacking.
- Most studies have small sample sizes, open-label designs, or lack active comparators, limiting generalizability.
- Long-term safety data, especially for psychedelic-assisted therapies, are insufficient.
- Optimal dosing intervals and maintenance protocols for ketamine/esketamine remain unclear.